Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
![Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”](https://www.biostock.se/wp-content/uploads/2024/03/Spago_radiopharma_commercial_opportunity.jpg)
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer.
The deal showcases rising interest in the field of radiopharmaceuticals.